auriga
  • Firm
  • Vision
  • Team
  • Portfolio
    • Software Investments
    • Life Sciences Investments
    • Combined Investments
    • Other
    • Luxury
  • CSR Policy
  • Contact
LIFE SCIENCES
COMBINED
OTHER
LUXURY
SOFTWARE

Amoéba

amoeba-biocide.com. Amoeba provides industry with the most powerful disruptive biocide to eliminate bacteria - Legionella, amoeba and biofilm- in water.
  • Listed on Euronext (France): AMEBA
  • ​Fund: AV IV Bioseeds Portfolio
Tweets by AmoebaBiocide

Cytoo

cytoo.com. ​CYTOO is a biotechnology company specialized in the development of physiologically-relevant cellular models and assays for High Content Screening (HCS).
  • ​Fund: AV III Portfolio
Tweets by CYTOO

Domain Therapeutics

domaintherapeutics.com. Domain Therapeutics is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.
  • ​Fund: AV II Portfolio
Tweets by DOMAINTherapeut

EnobraQ

enobraq.com. EnobraQ develops a baker's yeast that uses CO2 as carbon source and H2 as energy source.
  • Fund: AV IV Bioseeds Portfolio
Picture

Erytech Pharma

erytech.com. Erytech Pharma develops innovative cancer therapies ; its proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
  • Listed on Euronext (France): ERYP
  • Fund: AV III Portfolio
Tweets by ERYTECH_PHARMA

Evolva

evolva.com. Evolva discovers and provides innovative high value, sustainable ingredients, with an emphasis on health, wellness and nutrition.
  • Listed on SIX  (Swizterland): EVE
  • Exited
Tweets by EvolvaTweets

Exeliom Biosciences

exeliombio.com. Exeliom Biosciences develops a new class of microbiota-based innovative therapeutic products to treat inflammatory bowel diseases.
  • Fund: AV IV Bioseeds Portfolio
Picture

Fab'entech

fabentech.com. Fab'entech is a company specialized in passive immunotherapy based on specific polyclonal immunoglobulins  [F(ab')2]  against emerging infectious diseases.
  • Fund: AV IV Bioseeds Portfolio
Tweets by Fabentech
Picture

Firalis

firalis.com. Firalis is a biotechnology company with a mission to create novel values via biomarker discovery, development and regulatory qualification that ultimately lead to biomarker-based diagnostics.
  • Fund: AV III Portfolio
Tweets by FiralisGroup

Flash Therapeutics

flashtherapeutics.com. Flash Therapeutics is a gene therapy company developing new generation of non-integrative RNA carriers for therapeutic applications
  • Fund: AV IV Bioseeds Portfolio
Tweets by FlashTherapeutx

Gamida Cell

gamida-cell.com. Leader in immuno oncology, Gamida Cell develops treatments for orphan hematological diseases and malignancies using stem cells and NK cells.
  • Listed on Nasdaq (USA): GMDA
  • Fund: AV I Portfolio
Picture

Genocea

genocea.com. Genocea discovers and develops vaccines and immunotherapies using a transformational technology platform for T cell antigen discovery.
  • Listed on Nasdaq (USA): GNCA​
  • Exited
Tweets by GenoceaBio

Hybrigenics

hybrigenics.com. Bio-pharmaceutical company with a focus on research and development of new targets & therapies against proliferative diseases. Hybrigenic's current development program is based on inecalcitol, a vitamin D receptor agonist being studied in 3 potential applications (lymphocytic and myeloid leukaemia and prostate cancer) .
  • Listed on Alternext (France): ALHYG​
  • Exited
Picture

Icagen

icagen.com. Icagen offers industry-leading scientific expertise and comprehensive services for ion channel and transporter drug discovery and development.
  • Listed on Nasdaq (USA): ICGN
  • Exited
Tweets by icagen_inc

Innate Pharma

innate-pharma.com. Clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.
  • Listed on Euronext (France): IPH
  • Exited
Tweets by InnatePharma

Isocell

glisodine.fr. Isocell has developed a proprietary formulation for Super-Oxyde Dismutase (SOD); a powerful anti-oxydant for which formulation has always been the major stumbling block. Strong scientific evidence has shown the benefits of SOD namely (prevention of cardio-vascular diseases). The company is also targeting the functional food area (sodas, sports drinks, dairies ... with wellness claims).
  • Fund: AV III Portfolio
Picture

NicOx

nicox.com. Nicox is an international ophtalmic R&D company, aiming to build a diversified portofio of therapeutic products adressing the needs of eyecare practitioners and patients around the world.
  • Listed on Euronext (France): COX
  • Exited
Picture

Nosopharm

nosopharm.com. Innovative anti-infective drug discovery targeting the bacterial multidrug resistance to antibiotics.
  • Fund: AV IV Bioseeds Portfolio
Tweets by nosopharm

Novagali Pharma

santen.com. Innovative drug formulations to treat eye disorders.
  • Listed on Euronext (France): NOVA - Acquired by Santen, 2011
  • Exited
Picture

Onxeo

onxeo.com. Onxeo is a biopharmaceutical company specialist in the development of oncology products.
  • Listed on Euronext (France): ONXEO
  • Exited
Tweets by Onxeo_

Pherecydes Pharma

pherecydes-pharma.com. Pherecydes Pharma is an innovative company specialized in phage therapy developing phages to fight infections.​​
  • Listed on Euronext (France): ALPHE
  • Fund: AV IV Bioseeds Portfolio
Picture

PopulationGenetics

popgentech.com. Population Genetics has developed a broad portfolio of patents covering revolutionary technologies that will have a major impact on the use of next generation sequencing (NGS) for a broad range of applications.
  • Fund: AVIII Portfolio
Picture

Pylote

pylote.com. Pylote conceives and develops innovative mineral microspheres to sell solutions which can be integrated into numerous consumer products without any change to the existing manufacturing process.
  • Fund: AV IV Bioseeds Portfolio
Tweets by Pylote

Spine Next

abbott.com. Innovative Spine implants.
  • Acquired by Abbott, 2004 
  • ​Exited
Tweets by abbottglobal

Targacept

catalystbiosciences.com. Development of innovative neuronal nicotinic receptor-based therapies. Merged with Catalyst Biosciences.
  • Listed on Nasdaq (USA): CBIO
  • Exited
Tweets by catalystbio

Theranexus

theranexus.com. Theranexus has developed a versatile proprietary technology leading to first in class products to address severe unmet medical needs in brain disorders.
  • Fund: AV IV Bioseeds Portfolio
Picture

TiGenix

tigenix.com. TiGenix NV is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells.
  • ​Listed on Euronext (Belgium): TIG
  • Exited
Tweets by tigenix

TxCell

txcell.com. TxCell is a biotech company developing innovative celltherapy platforms based on regularoty T cells (Tregs) to treat severe autoimmune and inflammatory disorders.
  • Acquired by Sangamo Therapeutics, 2018
  • ​Fund: Exited
Tweets by SangamoTx

VitaDX

vitadx.com. VitaDX develops a non-invasive solution for early bladder cancer diagnosis.
  • Fund: AV IV Bioseeds Portfolio
Tweets by VitaDX_SA

© COPYRIGHT 2015. TOUS DROITS RÉSERVÉS.
  • Firm
  • Vision
  • Team
  • Portfolio
    • Software Investments
    • Life Sciences Investments
    • Combined Investments
    • Other
    • Luxury
  • CSR Policy
  • Contact